Royalty Report: Cancer, Drugs, Therapeutic – Collection: 91705

License Grant

Licensor hereby grants to Licensee an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.

License Property

Licensed Patent Rights  shall mean Patent Application Serial No. 62/258007 filed 11-20-2015 by Licensor.   Titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.  Product(s) Shall mean any materials including compositions, techniques, devices, methods or inventions relating to or based on the Licensed Patent Rights.

Field of Use

This agreement pertains to the drug industry relating to cancer.  The programs within Licensee include using exosomes derived from various immune cells to attack cancers as well as developing a cancer vaccine against cancers that express a certain protein unique to them.

License Grant

Licensor hereby grants to Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.  Patent Application is titled as “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”. Product Shall mean any materials including compositions, techniques, devices, methods or inventions relating to or based on the Licensed Patent Rights.

License Property

The invention teaches that cancer associated molecules, including production of glucocorticoids and HPA activation, have a general suppressive activity on the immune response which blocks ability to elicit effective anticancer immunity.

Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”.

The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.

Field of Use

Licensee desires to use the rights to MemoryMune, a product derived from donor blood cells, developed to reawake dormant immune memory cells to develop marketable Product(s).

Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patient’s own immune system.  Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.

License Grant

Licensor hereby grants to the Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.

License Property

The license is for Patent Application Serial No. 62/478532, titled as Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization and commercially named StemVacs.

The patent describes methods of cancer treatment through the administration of proteins or specific peptides found on tumor stem cells in vivo, in a manner eliciting monocyte or dendritic cell migration in order to allow uptake of proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.

Field of Use

This agreement is for the vaccine industry.

License Grant

The Licensee has been exclusively assigned all rights and title to and interest in an invention and related worldwide patent rights for a method to treat cancer under an assignment Agreement with the London Licensor. The invention provides for the 'Depression of anticancer immunity through extracorporeal removal of microvesicular particles' (including exosomes) for which a patent was allowed by the U.S. Patent and Trademark Office (USPTO) in 2012 and patent applications have been filed abroad by us.  Under the License Agreement, the Licensor sold and assigned all of its rights, title and interest in the worldwide patents to us.

License Property

The IP relates to a method to treat cancer.

Field of Use

The Licensee creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions.

License Grant

With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.

License Property

GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.

Field of Use

The focus of the compound in this agreement is for the treatment of cancer.

License Grant

The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.

License Property

Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.”

Field of Use

The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.